ANRO
Price
$2.35
Change
+$0.07 (+3.07%)
Updated
Apr 25 closing price
Capitalization
61.72M
24 days until earnings call
NUVL
Price
$73.48
Change
-$0.50 (-0.68%)
Updated
Apr 25 closing price
Capitalization
5.3B
12 days until earnings call
Ad is loading...

ANRO vs NUVL

Header iconANRO vs NUVL Comparison
Open Charts ANRO vs NUVLBanner chart's image
Alto Neuroscience
Price$2.35
Change+$0.07 (+3.07%)
Volume$141.91K
Capitalization61.72M
Nuvalent
Price$73.48
Change-$0.50 (-0.68%)
Volume$199.1K
Capitalization5.3B
ANRO vs NUVL Comparison Chart
Loading...
ANRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANRO vs. NUVL commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANRO is a Hold and NUVL is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (ANRO: $2.35 vs. NUVL: $73.48)
Brand notoriety: ANRO and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANRO: 41% vs. NUVL: 33%
Market capitalization -- ANRO: $61.72M vs. NUVL: $5.3B
ANRO [@Biotechnology] is valued at $61.72M. NUVL’s [@Biotechnology] market capitalization is $5.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $276.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANRO’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • ANRO’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, ANRO is a better buy in the long-term than NUVL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANRO’s TA Score shows that 4 TA indicator(s) are bullish while NUVL’s TA Score has 6 bullish TA indicator(s).

  • ANRO’s TA Score: 4 bullish, 3 bearish.
  • NUVL’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NUVL is a better buy in the short-term than ANRO.

Price Growth

ANRO (@Biotechnology) experienced а +3.98% price change this week, while NUVL (@Biotechnology) price change was +2.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.19%. For the same industry, the average monthly price growth was -3.08%, and the average quarterly price growth was -10.41%.

Reported Earning Dates

ANRO is expected to report earnings on May 20, 2025.

NUVL is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+8.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.3B) has a higher market cap than ANRO($61.7M). NUVL YTD gains are higher at: -6.132 vs. ANRO (-44.444). ANRO has higher annual earnings (EBITDA): -55.61M vs. NUVL (-280.37M). NUVL has more cash in the bank: 1.12B vs. ANRO (182M). ANRO (0) and NUVL (0) have equivalent revenues.
ANRONUVLANRO / NUVL
Capitalization61.7M5.3B1%
EBITDA-55.61M-280.37M20%
Gain YTD-44.444-6.132725%
P/E RatioN/AN/A-
Revenue00-
Total Cash182M1.12B16%
Total Debt16.8MN/A-
TECHNICAL ANALYSIS
Technical Analysis
ANRONUVL
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
73%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 23 days ago
90%
Bearish Trend 19 days ago
79%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 5 days ago
87%
View a ticker or compare two or three
Ad is loading...
ANRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JPC7.710.05
+0.65%
Nuveen Preferred & Income Opportunities Fund
OSCV34.150.08
+0.22%
Opus Small Cap Value Plus ETF
PSR89.32-0.20
-0.23%
Invesco Active US Real Estate
CPER30.38-0.23
-0.75%
United States Copper Index
BZQ12.69-0.15
-1.20%
ProShares UltraShort MSCI Brazil Capped

ANRO and

Correlation & Price change

A.I.dvisor tells us that ANRO and NUVL have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ANRO and NUVL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANRO
1D Price
Change %
ANRO100%
+3.07%
NUVL - ANRO
27%
Poorly correlated
-0.68%
XTLB - ANRO
27%
Poorly correlated
N/A
GUTS - ANRO
26%
Poorly correlated
-1.56%
PRME - ANRO
25%
Poorly correlated
-3.43%
BIVI - ANRO
24%
Poorly correlated
-6.06%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with ABCZF. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then ABCZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-0.68%
ABCZF - NUVL
51%
Loosely correlated
N/A
ROIV - NUVL
47%
Loosely correlated
+0.09%
KYMR - NUVL
47%
Loosely correlated
-0.89%
RVMD - NUVL
44%
Loosely correlated
+0.49%
CRNX - NUVL
44%
Loosely correlated
-2.99%
More